DAAs rapidly reduce inflammation but increase serum VEGF level: A rationale for tumor risk during anti-HCV treatment

PLoS ONE

Volumn 11, Issue 12, 2016, Pages

  Villani, Rosanna ^a   Facciorusso, Antonio ^a   Bellanti, Francesco ^a   Tamborra, Rosanna ^a   Piscazzi, Annamaria ^a   Landriscina, Matteo ^a,b   Vendemiale, Gianluigi ^a   Serviddio, Gaetano ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b REFERRAL CANCER CENTER OF BASILICATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; EPIDERMAL GROWTH FACTOR; INTERLEUKIN 10; LEDIPASVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TUMOR NECROSIS FACTOR; VASCULOTROPIN; IL10 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER RISK; CELL PROLIFERATION; CHRONIC HEPATITIS C; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; TREATMENT DURATION; UMBILICAL VEIN ENDOTHELIAL CELL; VIRAL CLEARANCE; VIREMIA; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; INTERLEUKIN-10; MALE; MIDDLE AGED; NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85006957518     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0167934     Document Type: Article

References (27)

1. Lawitz E, Makara M, Akarca US, Thuluvath PJ, Preotescu LL, Varunok P, et al. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis. Gastroenterology. 2015 Oct; 149(4): 971-80 e1. doi: 10.1053/j.gastro.2015.07.001 PMID: 26170136
2. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014 May 22; 370(21): 1973-82. doi: 10.1056/NEJMoa1402869 PMID: 24725237
3. Reddy KR, Bourliere M, Sulkowski M, Omata M, Zeuzem S, Feld JJ, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Hepatology. 2015 Jul; 62(1): 79-86. doi: 10.1002/hep.27826 PMID: 25846144
4. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr., et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015 Sep; 149(3): 649-59. doi: 10.1053/j.gastro.2015.05.010 PMID: 25985734
5. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016 May; 63(5): 1493-505. doi: 10.1002/hep.28446 PMID: 26754432
6. Reig M, Marino Z, Perello C, Inarrairaegui M, Ribeiro A, Lens S, et al. Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-fre therapy: a note of caution. J Hepatol. 2016 Apr 12.
7. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-Acting antivirals. J Hepatol. 2016 Jun 24.
8. Kozbial K, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, Stauber R, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-fre direct-Acting antiviral treatment. J Hepatol. 2016 Jun 16.
9. Agency EM. Direct-Acting antivirals indicated for treatment of hepatitis C (interferon-fre). 2016.
10. Pol S. Lack of evidence of an effect of Direct Acting Antivirals on the recurrence of hepatocellular carcinoma: The ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CIRVIR and CO23 CUPILT cohorts). J Hepatol. 2016 Jun 7.
11. Nault JC, Colombo M. Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution. J Hepatol. 2016 Jul 12.
12. Meissner EG, Kohli A, Virtaneva K, Sturdevant D, Martens C, Porcella SF, et al. Achieving sustained virologic response after interferon-fre hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis. J Viral Hepat. 2016 Jul; 23(7): 496-505. doi: 10.1111/jvh.12510 PMID: 26840694
13. Serti E, Park H, Keane M, O'Kefe AC, Rivera E, Liang TJ, et al. Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNalpha. Gut. 2016 Jan 4.
14. Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol. 2011 May; 8(5): 292-301. doi: 10.1038/nrclinonc.2011.30 PMID: 21386818
15. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005 Sep; 5(9): 558-67. doi: 10.1016/S1473-3099(05)70216-4 PMID: 16122679
16. European Association for Study of L. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul; 63(1): 199-236. doi: 10.1016/j.jhep.2015.03.025 PMID: 25911336
17. Lichtenberger BM, Tan PK, Niederleithner H, Ferrara N, Petzelbauer P, Sibilia M. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell. 2010 Jan 22; 140(2): 268-79. doi: 10.1016/j.cell.2009.12.046 PMID: 20141840
18. Mise M, Arii S, Higashituji H, Furutani M, Niwano M, Harada T, et al. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology. 1996 Mar; 23(3): 455-64. doi: 10.1053/jhep.1996.v23.pm0008617424 PMID: 8617424
19. Park YN, Kim YB, Yang KM, Park C. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med. 2000 Jul; 124 (7): 1061-5. doi: 10.1043/0003-9985(2000)1242.0.CO;2 PMID: 10888784
20. Schmitt M, Horbach A, Kubitz R, Frilling A, Haussinger D. Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion. J Hepatol. 2004 Aug; 41(2): 274-83. doi: 10.1016/j.jhep.2004.04.035 PMID: 15288477
21. Serti E, Chepa-Lotrea X, Kim YJ, Keane M, Fryzek N, Liang TJ, et al. Successful Interferon-Fre Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. Gastroenterology. 2015 Jul; 149(1): 190-200 e2. doi: 10.1053/j.gastro.2015.03.004 PMID: 25754160
22. Meissner EG, Wu D, Osinusi A, Bon D, Virtaneva K, Sturdevant D, et al. Endogenous intrahepatic IFNs and association with IFN-fre HCV treatment outcome. J Clin Invest. 2014 Aug; 124(8): 3352-63. doi: 10.1172/JCI75938 PMID: 24983321
23. Sato T, Terai M, Tamura Y, Alexev V, Mastrangelo MJ, Selvan SR. Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res. 2011 Dec; 51(2-3): 170-82. doi: 10.1007/s12026-011-8262-6 PMID: 22139852
24. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med. 2006 Nov; 12(11): 1301-9. doi: 10.1038/nm1492 PMID: 17041596
25. Ejrnaes M, Filippi CM, Martinic MM, Ling EM, Togher LM, Crotty S, et al. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med. 2006 Oct 30; 203(11): 2461-72. doi: 10.1084/jem.20061462 PMID: 17030951
26. Blackburn SD, Wherry EJ. IL-10, T cell exhaustion and viral persistence. Trends Microbiol. 2007 Apr; 15(4): 143-6. doi: 10.1016/j.tim.2007.02.006 PMID: 17336072
27. Nelson DR, Tu Z, Soldevila-Pico C, Abdelmalek M, Zhu H, Xu YL, et al. Long-Term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology. 2003 Oct; 38 (4): 859-68. doi: 10.1053/jhep.2003.50427 PMID: 14512873